(1R)-N-[(6-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-(oxan-4-yl)-1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)methanamine
C20H27N5O2 — CID 129338503
Data last refreshed: (MolForge compound catalog, from PubChem)
About (1R)-N-[(6-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-(oxan-4-yl)-1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)methanamine
(1R)-N-[(6-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-(oxan-4-yl)-1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)methanamine (PubChem CID 129338503) has the molecular formula C20H27N5O2 and a molecular weight of 369.47 g/mol. Its IUPAC name is (1R)-N-[(6-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-(oxan-4-yl)-1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)methanamine.
Molecular Properties
| Compound Name | (1R)-N-[(6-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-(oxan-4-yl)-1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)methanamine |
|---|---|
| PubChem CID | 129338503 |
| Molecular Formula | C20H27N5O2 |
| Molecular Weight | 369.47 g/mol |
| Exact Mass | 369.22 |
| IUPAC Name | (1R)-N-[(6-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-(oxan-4-yl)-1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)methanamine |
| SMILES | Cc1ccc2ncc(CN[C@@H](c3nc(C(C)C)no3)C3CCOCC3)n2c1 |
| InChI | InChI=1S/C20H27N5O2/c1-13(2)19-23-20(27-24-19)18(15-6-8-26-9-7-15)22-11-16-10-21-17-5-4-14(3)12-25(16)17/h4-5,10,12-13,15,18,22H,6-9,11H2,1-3H3/t18-/m1/s1 |
| InChIKey | UORMIGSWUPFMNT-GOSISDBHSA-N |
| XLogP | 3.41 |
| TPSA | 77.48 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 369.47 |
| LogP ≤ 5 | 3.41 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 129338503 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.